"covid 19"completion of activ 2 study
Ended Awarded Last action
- Contract number
- 75N93022F00002
- Awardee
-
PPD Development LP UEI ZANENSW6C665
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $64,031,927
Award facts
- Opportunity
-
- Feasibility of Restoring Postal Service Standards Solicitation · 202301 · Posted Sep 23, 2022
- Contract value 100% obligated
- $64,031,927.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Cape Fear, NC 28401, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$18,500,000 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $82,531,927 |
About this award
The National Institute of Allergy and Infectious Diseases awarded a $64.0 million delivery order to PPD Development LP on November 6, 2022, to complete the ACTIV-2 COVID-19 study. This delivery order, structured as a cost-plus-fixed-fee contract, carries a completion deadline of August 31, 2025, and is being performed in Cape Fear, North Carolina. PPD Development LP, a global contract research organization and subsidiary of Thermo Fisher Scientific, was selected without set-aside designation, reflecting its status as a large business capable of competing for unrestricted federal procurements. The company specializes in comprehensive clinical research services, regulatory affairs, and federal support across multiple therapeutic domains including infectious diseases and medical countermeasures development.
This delivery order is issued under PPD Development LP's broader indefinite delivery/indefinite quantity vehicle from NIAID valued at $545.5 million for comprehensive and rapid response capabilities through August 2028. The ACTIV-2 study represents a significant component of the federal government's COVID-19 research response, leveraging PPD's extensive experience managing large-scale clinical trials and federal research programs. The contractor's substantial portfolio of federal awards, including hundreds of millions in active contracts across the National Institutes of Health, Department of Defense, and other agencies, demonstrates its established capability to execute mission-critical clinical research initiatives for the federal government.
Quick answers
Who was awarded contract 75N93022F00002?
75N93022F00002 was awarded to PPD Development LP by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on November 6, 2022.
How much is contract 75N93022F00002 worth?
The government has obligated $64,031,927 on 75N93022F00002.
Is contract 75N93022F00002 an order under another contract?
Yes. 75N93022F00002 is a delivery order under 75N93021D00035, an indefinite delivery contract.
Was contract 75N93022F00002 competed?
The extent of competition for 75N93022F00002 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award